May 20 (Reuters) - BridgeBio Pharma Inc BBIO.O:
ACORAMIDIS REDUCED INCIDENCE OF ATRIAL FIBRILLATION EVENTS IN PATIENTS WITH ATTR-CM
BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES ANNUAL CVH FREQUENCY DUE TO AF/AFL BY 43%
BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES NEW-ONSET AF/AFL INCIDENCE BY 17%
BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES ACM AND CVH EVENTS BY 42% AT MONTH 30
Source text: ID:nGNX1RJk6
Further company coverage: BBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.